Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Using the Advocacy Coalition Framework to understand EU pharmaceutical policy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Brooks E;Brooks E
  • Source:
    European journal of public health [Eur J Public Health] 2018 Nov 01; Vol. 28 (suppl_3), pp. 11-14.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: England NLM ID: 9204966 Publication Model: Print Cited Medium: Internet ISSN: 1464-360X (Electronic) Linking ISSN: 11011262 NLM ISO Abbreviation: Eur J Public Health Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Oxford University Press
      Original Publication: Stockholm, Sweden : Almqvist & Wiksell International, c1991-
    • Subject Terms:
      Drug and Narcotic Control* ; Health Policy* ; Policy Making* ; Public Health*; European Union ; Humans ; Pharmaceutical Preparations
    • Abstract:
      Models of interest group politics can help public health professionals (PHPs) to identify potential allies and establish mechanisms of sustainable political influence. This article focusses on a particular model, known as the Advocacy Coalition Framework (ACF), and its explanations of coalition behaviour, the role of scientific information and the ways in which coalitions can bring about policy change. The analysis illustrates the relevance of the ACF for public health by drawing on examples from the recent policy debate on direct-to-consumer advertising of prescription drugs (DTCA-PD) in the European Union (EU). It explores the strengths and weaknesses of the ACF in explaining why 'control' of particular governmental units was key to the anti-DTCA coalition success, how the evidence base was used strategically and why the pro-DTCA coalition ultimately failed in bringing about major policy change. The article aims to equip PHPs with a tool which can be used to understand and engage with the policy process. Moreover, in offering a more nuanced view of this process, a case is made for moving beyond traditional, linear conceptions of the policy process and engaging in further research which uses political science concepts to inform the study and practice of public health. The article concludes with a set of recommendations for practitioners and researchers, emphasizing the value of political science for the former and the need for the latter to reflect on the accessibility of policy studies for PHPs.
    • References:
      Health Res Policy Syst. 2017 Apr 26;15(1):35. (PMID: 28446185)
      Future Med Chem. 2009 Jul;1(4):587-92. (PMID: 21426028)
      BMJ. 2002 Apr 13;324(7342):910-1. (PMID: 11950746)
      BMC Public Health. 2013 Nov 14;13:1074. (PMID: 24225055)
      J Am Board Fam Pract. 2004 Jan-Feb;17(1):6-18. (PMID: 15014047)
      J Eval Clin Pract. 2012 Dec;18(6):1235-40. (PMID: 22816868)
      Clin Pharmacol Ther. 2007 Oct;82(4):360-2. (PMID: 17851573)
      Ann Fam Med. 2007 Jan-Feb;5(1):6-13. (PMID: 17261859)
      Health Promot Int. 2011 Mar;26(1):109-16. (PMID: 21296911)
      BMJ. 2002 Feb 2;324(7332):278-9. (PMID: 11823361)
      PLoS Med. 2006 Apr;3(4):e189. (PMID: 16597179)
      BMJ. 2014 Sep 15;349:g5671. (PMID: 25223390)
      Sociol Health Illn. 2013 Jun;35(5):761-77. (PMID: 23094890)
      Int J Health Policy Manag. 2017 Sep 06;7(3):288-289. (PMID: 29524962)
      BMC Health Serv Res. 2014 Jan 03;14:2. (PMID: 24383766)
      Int J Health Policy Manag. 2017 Apr 05;6(9):495-499. (PMID: 28949461)
    • Accession Number:
      0 (Pharmaceutical Preparations)
    • Publication Date:
      Date Created: 20181102 Date Completed: 20190219 Latest Revision: 20190320
    • Publication Date:
      20231215
    • Accession Number:
      PMC6209818
    • Accession Number:
      10.1093/eurpub/cky153
    • Accession Number:
      30383259